Keros Therapeutics, Inc. (KROS)
10.78
-0.25
(-2.27%)
USD |
NASDAQ |
Aug 24, 16:00
10.79
+0.01
(+0.09%)
Pre-Market: 20:00
Keros Therapeutics Revenue (Quarterly) : 0.00 for June 30, 2026
Revenue (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.367M |
| December 31, 2025 | 0.385M |
| September 30, 2025 | 14.26M |
| June 30, 2025 | 18.17M |
| March 31, 2025 | 211.25M |
| December 31, 2024 | 3.042M |
| September 30, 2024 | 0.388M |
| June 30, 2024 | 0.037M |
| March 31, 2024 | 0.083M |
| December 31, 2023 | 0.143M |
| September 30, 2023 | 0.008M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 20.00M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.10M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 2.50M |
| September 30, 2019 | 2.50M |
| June 30, 2019 | 2.50M |
| March 31, 2019 | 2.50M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Revenue (Quarterly) Benchmarks
| Incyte Corp. | 1.674B |
| Nurix Therapeutics, Inc. | 9.043M |
| ACADIA Pharmaceuticals, Inc. | 307.96M |
| Alnylam Pharmaceuticals, Inc. | 1.291B |
| Anika Therapeutics, Inc. | 32.61M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -28.71M |
| Total Expenses (Quarterly) | 28.71M |
| EPS Diluted (Quarterly) | -1.45 |
| Enterprise Value | -28.14M |
| Earnings Yield | -34.32% |
| Normalized Earnings Yield | -34.30 |